To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

Korábbi kezelés

• Patients who discontinued a prior Zepzelca treatment due to adverse events.
• Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule.
• Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca.
• Known CNS involvement prior to Zepzelca treatment.
• Patients who were treated with Zepzelca in later lines rather than in second-line treatment

• Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information.
• Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study.
• Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.
• Patients initiating Zepzelca treatment in second-line.
• Patients who are sensitive to platinum-based chemotherapy with CTFI≥180 days. The CTFI is defined as the length of time from last platinum dose to time of relapse or disease progression.
• Eastern Cooperative Oncology Group performance status (ECOG) ≤1